Company news
Mabwell (Shanghai) Bioscience Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(688062)"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
October 29, 2026
(688062)"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Report for Q3 2026
October 28, 2026
(688062)"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Resolutions of the 4th Meeting of the 3rd Board of Directors
October 28, 2026
(688062)"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Extension of Certain Raised Funds Investment Project
October 28, 2026
(688062)"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Voluntary Disclosure of the Oral Presentation of Clinical Data for 9MW2821 at the 2026 European Society for Medical Oncology (ESMO) Congress
October 18, 2026
(688062)"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Listing and Trading of Certain Restricted Shares from the Initial Public Offering
October 15, 2026
(688062)"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on External Investment and Introduction of Investors to Lianwei Chuangyuan
September 28, 2026
Announcement on Resolutions of the 3rd Meeting of the 3rd Board of Directors
September 28, 2026
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2026
September 17, 2026
ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients
September 4, 2026
Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 1, 2026
Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026
August 30, 2026
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
August 8, 2026
Announcement on Voluntary Disclosure of the Approval by the National Medical Products Administration of the Clinical Trial Application for 9MW5211 Injection
July 15, 2026
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
June 25, 2026
Announcement on Voluntary Disclosure of Clinical Trial Applications for 9MW5211 Injection Approved by China NMPA
June 24, 2026
Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
June 22, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
June 22, 2026
Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
June 18, 2026
Announcement on Voluntary Disclosure of FDA Approval for the Clinical Trial Application for 6MW5311 Injection
June 12, 2026
Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
June 4, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
June 1, 2026
Announcement on Engagement of H-share Audit Institution for 2026
May 29, 2026
Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
May 21, 2026
Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection)
May 19, 2026
World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application
May 7, 2026
Notice on Convening the 2nd Extraordinary General Meeting in 2026
May 6, 2026
2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
April 30, 2026
Report for Q1 2026
April 28, 2026
Announcement on the Public Offering Price of Overseas Listed Foreign Shares (H-shares)
April 24, 2026
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
April 23, 2026
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
April 23, 2026
Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
April 21, 2026
Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
April 20, 2026
Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market
April 16, 2026
Global First | NMPA Accepts IND Application for Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
April 15, 2026
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
April 15, 2026
Announcement on Voluntary Disclosure of Acceptance Supplementary Application for Increasing the Indications of Denosumab Injection (MAIWEIJIAN)
April 15, 2026
SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial
April 14, 2026
Announcement on Resolutions of the 30th Meeting of the 2nd Board of Directors
April 7, 2026
2025 Annual Report
March 24, 2026
Announcement on the Results of Issuance of the 2026 Phase I Targeted Science and Technology Innovation Bonds
March 23, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 13, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
January 28, 2026
Earnings Preannouncement for 2025
January 23, 2026
Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.
January 22, 2026
Announcement on Continuing to Use Some Temporarily Idle Raised Funds for Cash Management
January 21, 2026
Mabwell's Adalimumab Biosimilar Receives Marketing Approval in Indonesia
December 31, 2025
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring
December 30, 2025